Clinical trial · Observational
Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to evaluate the effectiveness of SHAReClinic, a national, virtual Sexual Health and Rehabilitation eClinic designed to support prostate cancer patients and their partners. Specifically, this study aims to assess SHAReClinic's impact on improving sexual function, satisfaction, and relational intimacy after treatment. The primary objective is to evaluate SHAReClinic's effectiveness across participating sites and determine its role in supporting long-term sexual health and well-being. As part of usual care, newly enrolled SHAReClinic patients will receive guided education modules and access to sexual health counselling at key recovery milestones. SHAReClinic seeks to expand access to sexual health care for prostate cancer patients across Canada by providing evidence-based, virtual sexual rehabilitation. Findings from this study will inform best practices in survivorship care and contribute to the development of a national standard for oncology sexual health interventions.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Implementation | — | UNRESOLVED | — |
| Implementation of Evidence Based Programs | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Sexual Dysfunction | — | UNRESOLVED | — |
| Sexual Dysfunction, Physiological | — | UNRESOLVED | — |
| Sexual Dysfunction, Psychological | — | UNRESOLVED | — |
| Survivorship | — | UNRESOLVED | — |
| Virtual Care | — | UNRESOLVED | — |
| Virtual Clinic | — | UNRESOLVED |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Assessing SHAReClinic's Impact on Sexual Function and Satisfaction
- timeFrame
- Baseline, 6 weeks, 6 months, and 12 months
- description
- Measured using: PROMIS-20 Full Profile Sexual Function and Satisfaction (Male) This outcome assesses sexual function and satisfaction across multiple domains, including erectile function, orgasm, and overall sexual activity. Each item is scored on a 5-point Likert scale, and raw scores are converted to T-scores (Mean = 50, SD = 10). A higher T-score indicates better sexual function and satisfaction. The measure is collected at multiple time points to track changes in sexual function over time.
- measure
- Assessing SHAReClinic's Impact on Sexual Distress
- timeFrame
- Baseline, 6 weeks, 6 months, and 12 months
- description
- Measured using: Sexual Distress Scale (SDS - Male) This outcome measures the level of distress related to sexual function, including anxiety and emotional responses to changes in sexual activity post-treatment. Items are rated on a 5-point scale, and total scores are summed. A higher score indicates greater sexual distress, meaning that patients experiencing more distress will have higher numerical values. This outcome is assessed periodically to evaluate changes over time.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who are scheduled for first-line treatment for localized prostate cancer, either through radical prostatectomy (open or robotic) or radiation treatment (brachytherapy, external beam) Alone, or with adjuvant Androgen Deprivation Therapy (ADT) OR * Patients currently undergoing active treatment for prostate cancer OR * Patients who have undergone cancer treatment in the past 6 months * Patients who are hormone and/or chemotherapy-naïve * Patients who have access to a computer or smartphone with internet access * Patients who are 18 years of age or older Exclusion Criteria: * Patients on ADT alone as primary treatment, and/or patients on chemotherapy * Patients who lack English proficiency * Patients on nitrate therapy or have other contra-indications to phosphodiesterase type 5 inhibitors (PDE5i's) * Patients with medical conditions that would preclude safe sexual activity * Patients who have had previous treatment for PCa
References
Publications (0)
Data not yet available